GSK
earnings
- 8 Owners
- Rank #150
- Max 3.5%
- Master 0.15%
No earnings events stored for GSK yet.
The name is tracked in the universe; consensus prints appear when the provider has them.
Who owns this now
Largest portfolio weights among featured holders · max 3.5% (Hillman Capital Management) · not free-float ownership
SEC filings
Recent issuer filings from EDGAR · 25 shown · open Filing / Doc on SEC.gov
| Filed | Form | Detail | Links |
|---|---|---|---|
| 424B2 | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER | Filing Doc | |
| 6-K | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | 2ND QUARTER RESULTS | Filing Doc | |
| 6-K | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ | Filing Doc | |
| 6-K | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE | Filing Doc | |
| 6-K | ADMISSION TO TRADING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS | Filing Doc | |
| 6-K | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE | Filing Doc | |
| 6-K | CAMLIPIXANT PHASE III RESULTS UPDATE | Filing Doc | |
| 6-K | AUDIT TENDER CONCLUSION | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | GSK COMPLETES ACQUISITION OF NUVALENT, INC | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc |
No filings match this filter.
Consensus estimates · SEC filings remain the official record · not investment advice